Method for detecting heterogeneity in triple-negative breast cancer

Abstract

The invention discloses a method for detecting intratumoral heterogeneity of triple-negative breast cancer. The method solidifies tissue samples from different parts of the same patient on the same tissue chip, and then performs immunohistochemistry on the tissue chip. , immunofluorescence, fluorescence in situ hybridization and other detection. Effectively reduce the cost of experiments, save time and manpower, and also reduce errors caused by batch experiments, improve the consistency of experimental results, and achieve better quality control. This method uses multi-probe combined with fluorescence in situ hybridization technology to evaluate the intratumoral heterogeneity of triple-negative breast cancer, which reduces the dependence on expensive equipment and investment costs, and is easy to be widely promoted. The invention quantitatively detects intratumoral heterogeneity of triple-negative breast cancer, and provides a clear evaluation index for accurately predicting postoperative recurrence and metastasis risk of patients.

Description

technical field [0001] The invention relates to the field of breast cancer prognosis predictors, in particular to a method for quantitatively detecting intratumoral heterogeneity of breast cancer patients, specifically, a method for detecting intratumoral heterogeneity of triple-negative breast cancer. Background technique [0002] Breast cancer is one of the common malignant tumors. According to the latest statistics from WHO, there are about 180,000 new cases of female breast cancer in my country each year, ranking second in the incidence of female malignant tumors. Its treatment and prognosis have attracted widespread attention. [0003] Breast cancer is a highly heterogeneous disease, and its prognosis is closely related to factors such as different subtypes (ER, PR, HER-2 receptor status), tumor stage, proliferation index (Ki-67), histological grade, etc. . However, when the above factors are consistent, especially for ER, PR, HER-2-negative triple-negative breast can...

AI Technical Summary

Problems solved by technology

However, there is currently no uniform method for quantitatively detecting intratumoral heterogeneity in tumors, and most current research methods have the following shortcomings:

[0005] 1. In view of the spatial heterogeneity inside the tumor, it is often necessary to collect materials from multiple points in clinical practice, and then analyze the gene molecular level of a single sample separately. The time cost, economic cost, and labor cost of the whole process are greatly increased, and it will also increase Experimental error

[0006] 2. At present, more advanced methods for exploring intratumoral heterogeneity include whole-gene expression profiling, whole-genome or exome sequencing, and some even single-cell sequencing. Difficult to achieve ubiquity, lack of practicality

[0007] 3. At present, there is no uniform standard for judging tumor prognosis by intratumoral heterogeneity, and it has not been applied in triple-negative breast cancer

Images